DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election of claims 1-5 in the reply filed on 29 September 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 6-13 are withdrawn from consideration.
Information Disclosure Statement
The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 at line 2 recites the limitation "the expression". There is insufficient antecedent basis for this limitation in the claim.
Claim 5 recites “wherein the electric field stimulation is applied following A3AR agonist delivery”. This recitation is unclear since claim 1 appears to imply that the electric field stimulation is provided (at line 2), and then A3AR agonist delivery follows that step of providing (as recited at line 4 of claim 1). Therefore in claim 5, it is unclear which step of the method is to be performed first.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim 1 is rejected under 35 U.S.C. 103 as being unpatentable over “The Anti-Tumor Effect of A3 Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells” (Vincenzi et al.). Regarding claim 1, Vincenzi et al. (hereinafter Vincenzi) teaches a method of treating a cancerous tumor in a patient, comprising:
providing pulsed electric field stimulation to the tumor to increase the expression of A3ARs on a surface of cancer cells of the tumor (pg. 2, col. 2, 1st paragraph; also see pg. 1, 1st paragraph under “Introduction”); and
delivering a dose of A3AR agonist to induce apoptosis of the cancer cells of the tumor. While Vincenzi does not disclose the explicit step of delivering the dose to the patient, Vincenzi makes such obvious as Vincenzi discloses that “…preclinical and Phase I studies showed that A3AR agonists are safe and well tolerated in humans and thus may be considered possible therapeutic agents for certain cancer diseases” (pg. 1, last sentence of first paragraph under “Introduction”; also see pg. 11, 1st col. 2nd paragraph beginning with “Despite the increasing amount….”; and pg. 11, 2nd col., 1st paragraph beginning with “These results…”). Therefore, it would be obvious to deliver the dose to the patient in order to render therapeutic efficacy in a human patient.
It is also noted that the recitations “…to increase the expression of A3ARs on a surface of cancer cells of the tumor” and “…to induce apoptosis of the cancer cells of the tumor” are limitations which can be construed as intended use based on how they are recited.
Claims 2 and 5 are rejected under 35 U.S.C. 103 as being unpatentable over “The Anti-Tumor Effect of A3 Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells” (Vincenzi et al.) in view of Ilmoniemi et al. (U.S. Pub. No. 2014/0357935).
Regarding claim 2, while Vincenzi teaches the step of providing electric field stimulation to the tumor comprises arranging a first coil and a second coil secured in an applicator, wherein the planes of the coils are perpendicular to the cells, Vincenzi fails to disclose explicitly a third coil secured in the applicator, wherein the coils are secured in the applicator on three mutually orthogonal planes.
Ilmoniemi et al. (hereinafter Ilmoniemi) discloses a pulsed electric field stimulation (EFS) apparatus for treatment of cancer, the apparatus comprising: an applicator 90, comprising: a first coil (of module 93a) provided to the applicator in a first plane; a second coil (of module 93c) provided to the applicator in a second plane; and a third coil (of module 93e) provided to the applicator in a third plane, wherein each of the first, second and third planes are mutually orthogonal to one another (Fig. 9, [0096] and [0099]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate a third coil secured to an applicator, in a orthogonal plane relative to the other two coils as taught by Ilmoniemi, in a coil arrangement for targeting a particular stimulation target in a patient as suggested by Vincenzi as Ilmoniemi recognizes that such an arrangement of coils in an applicator helmet enables fitting the coils to different sized heads of patients having targeted brain therapy [0097]-[0099] and Vincenzi recognizes placing the target in between the coils (pg. 11, paragraph under “Electromagnetic Field Exposure System”).
Regarding claim 5, Vincenzi teaches wherein the electric field stimulation is applied following A3AR agonist delivery (text of pgs. 3, 9-11).
Allowable Subject Matter
Claims 3 and 4 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: U.S. Pub. No. 2007/0260107.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINE HOPKINS MATTHEWS whose telephone number is (571)272-9058. The examiner can normally be reached Monday - Friday, 7:30 am - 4:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles A Marmor, II can be reached at (571) 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CHRISTINE H MATTHEWS/Primary Examiner, Art Unit 3791